439908-92-6

Basic information

• Product Name: 3-(R)-(butyl(phenyl)carbamoyloxy)-1-(3-thiophen-2-ylpropyl)-1-azoniabicyclo[2.2.2]octane bromide
• Synonyms: 3-(R)-(butyl(phenyl)carbamoyloxy)-1-(3-thiophen-2-ylpropyl)-1-azoniabicyclo[2.2.2]octane bromide
• CAS NO: 439908-92-6
• Molecular Weight: 507.535
• Mol File: 439908-92-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(R)-(butyl(phenyl)carbamoyloxy)-1-(3-thiophen-2-ylpropyl)-1-azoniabicyclo[2.2.2]octane bromide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(R)-(butyl(phenyl)carbamoyloxy)-1-(3-thiophen-2-ylpropyl)-1-azoniabicyclo[2.2.2]octane bromide(439908-92-6)
• EPA Substance Registry System: 3-(R)-(butyl(phenyl)carbamoyloxy)-1-(3-thiophen-2-ylpropyl)-1-azoniabicyclo[2.2.2]octane bromide(439908-92-6)

Safety Data

• Hazardous Substances Data: 439908-92-6(Hazardous Substances Data)

Upstream product

• 62-53-3 aniline 
• 4275-07-4 N-butylideneaniline 
• 1126-78-9 N-(n-butyl)aniline 
• 55240-28-3 butyl-phenyl-carbamoyl chloride 
• 439908-47-1 butylphenylcarbamic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester 
• 30134-51-1 3-(thien-2-yl)propyl bromide 

Relevant articles and documents

Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl carbamates as potent and long acting muscarinic antagonists

Novel quaternary ammonium derivatives of N,N-disubstituted (3R)-quinuclidinyl carbamates have been identified as potent M3 muscarinic antagonists with long duration of action in an in vivo model of bronchoconstriction. These compounds have also presented a high level of metabolic transformation (human liver microsomes). The synthesis, structure-activity relationships and biological evaluation of these compounds are reported.

NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME

Carbamates of formula (I) or pharmaceutically acceptable salts thereof, including quaternary ammonium salts of formula (II) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of M3 muscarinic receptors.